Please login to the form below

Not currently logged in
Email:
Password:

NICE set to dismiss Millennium’s Crohn’s drug Entyvio

Body cites uncertain evidence and unlikely value for the NHS
Entyvio Vedolizumab

The National Institute for Health and Care Excellence (NICE) has issued draft guidance that recommends against the use of Millennium Pharmaceuticals' Entyvio on the NHS for patients with Crohn's disease.

The healthcare guidance body cited uncertain evidence and the unlikely nature that the drug would represent good value for the NHS as reasons for its decision.

The decision comes despite Millennium, a division of Japanes firm Takeda, agreeing to provide a discount for the list price of the drug via a patient access scheme.

Entyvio is targeted for adults with moderately to severely active Crohn's disease whose disease has responded inadequately to, or has lost response to, conventional therapy or a tumour necrosis factor-alpha inhibitor. It is also appropriate for those who cannot tolerate either of these treatments.

Professor Carole Longson, director of NICE's health technology evaluation centre, said: “Unfortunately the maker of vedolizumab did not give the committee enough information to show how well it worked when compared to other treatments. We have to be sure that a drug is both effective and cost-effective before it can be recommended.”

Of particular concern for NICE was the uncertainty that Entyvio worked as well as other currently available treatments.

In May last year the European Commission approved Entyvio to treat adults with ulcerative colitis and Crohn's disease following the FDA's approval for the drug in the US.

Entyvio marks a breakthrough in the treatment of Crohn's disease as existing treatments aim to stop the inflammatory process, relieve symptoms and avoid surgery, rather than tackle the underlying cause as Entyvio is intended.

Article by
Kirstie Pickering

7th January 2015

From: Sales, Healthcare

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

Harness the power of data to map new patient pathways
Oli Hudson, of Wilmington Healthcare, explains why pharma needs to put data at the heart of its bid to support the NHS Reset...
What NORD’s RareInsights® 30-year comparative analysis means to us and our clients at OPEN Health
...
Peter Jackson
Rethinking our approach to infectious disease preparedness
The importance of long-term strategic investment to prepare for the next threat that emerges...

Infographics